Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s stock price was up 7.5% on Wednesday. The company traded as high as $22.40 and last traded at $22.2070. 357,603 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 2,040,564 shares. The stock had previously closed at $20.65.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on BEAM. HC Wainwright reissued a “buy” rating on shares of Beam Therapeutics in a research note on Tuesday, October 27th. Wall Street Zen cut shares of Beam Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 31st. Wedbush upped their price target on shares of Beam Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Wednesday, November 11th. William Blair upgraded shares of Beam Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Beam Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $47.64.
Read Our Latest Report on BEAM
Beam Therapeutics Stock Down 0.3%
The company has a debt-to-equity ratio of 0.11, a current ratio of 13.01 and a quick ratio of 13.00. The stock’s 50 day moving average price is $24.70 and its two-hundred day moving average price is $27.71.
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.11). The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $8.75 million. Beam Therapeutics had a negative net margin of 73.04% and a negative return on equity of 32.76%. Beam Therapeutics’s quarterly revenue was down 96.8% on a year-over-year basis. During the same period last year, the firm earned ($1.10) EPS. As a group, analysts anticipate that Beam Therapeutics Inc. will post -4.65 EPS for the current year.
Insider Transactions at Beam Therapeutics
In other Beam Therapeutics news, CEO John Evans sold 25,000 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.57, for a total transaction of $589,250.00. Following the transaction, the chief executive officer owned 1,047,205 shares in the company, valued at approximately $24,682,621.85. This represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 3.80% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Beam Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of BEAM. Versant Capital Management Inc increased its stake in shares of Beam Therapeutics by 123.6% in the third quarter. Versant Capital Management Inc now owns 1,239 shares of the company’s stock worth $30,000 after purchasing an additional 685 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in Beam Therapeutics in the second quarter valued at approximately $43,000. Global Retirement Partners LLC lifted its stake in shares of Beam Therapeutics by 297.3% in the third quarter. Global Retirement Partners LLC now owns 1,490 shares of the company’s stock worth $36,000 after buying an additional 1,115 shares in the last quarter. Fulcrum Asset Management LLP acquired a new stake in shares of Beam Therapeutics during the 3rd quarter worth about $51,000. Finally, Nykredit A S purchased a new position in Beam Therapeutics in the second quarter valued at $75,000. 99.68% of the stock is currently owned by hedge funds and other institutional investors.
Beam Therapeutics Company Profile
Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.
Featured Articles
- Five stocks we like better than Beam Therapeutics
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
